EUCTR2010-021936-33-DE进行中（未招募）不适用
A multi-center randomized, double-blind, placebo controlled, parallel-group study of CD 07743 for the improvement of Lateral Canthal Lines (crow’s feet)
Galderma R&D SNC0 个研究点目标入组 324 人开始时间: 2010年11月19日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 324
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male and female subjects, 18 to 65 years of age with moderate or severe (grade 2 or 3) Lateral Canthal Lines at maximum smile and with mild to severe (grade 1, 2, or 3) Lateral Canthal Lines at rest.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects who had any prior surgery affecting the orbicularis oculi muscle, prior blepharoplasty or brow lift, or any prior cosmetic procedures or scars that may interfere with the evaluation of the study results will not be included in this study
研究者
相似试验
进行中（未招募）
不适用
A multi-center randomized, double-blind, placebo controlled, parallel-group study of CD 07743 for the improvement of Lateral Canthal Lines (crow’s feet)Moderate to severe Lateral Canthal LinesMedDRA version: 12.1Level: LLTClassification code 10052609Term: Glabellar frown linesEUCTR2010-021936-33-GBGalderma R&D SNC324
进行中（未招募）
不适用
A multi-center, randomized, double-blind placebo controlled study to evaluate the efficacy and safety of 24 weeks treatment with vildagliptin 50 mg bid as add-on therapy to metformin plus glimepiride in patients with type 2 diabetesEUCTR2010-021097-11-HUovartis Pharma Services AG290
进行中（未招募）
不适用
A multi-center, randomized, double-blind placebo controlled study to evaluate the efficacy and safety of 24 weeks treatment with vildagliptin 50 mg bid as add-on therapy to metformin plus glimepiride in patients with type 2 diabetesEUCTR2010-021097-11-DEovartis Pharma Services AG290
进行中（未招募）
不适用
A multi-center, randomized, double-blind placebo controlled study to evaluate the efficacy and safety of 24 weeks treatment with vildagliptin 50 mg bid as add-on therapy to metformin plus glimepiride in patients with type 2 diabetesType II Diabetes MellitusEUCTR2010-021097-11-GBovartis Pharma Services AG290
进行中（未招募）
不适用
YAZ Acne in ChinaEUCTR2014-004612-10-Outside-EU/EEABayer HealthCare AG172